Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
J Clin Pharmacol ; 64(2): 227-239, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37867371

ABSTRACT

The optimal therapeutic management of cyclic vomiting syndrome (CVS) remains elusive. The objective of this study was to document our clinical experience in the Pediatric Department of San Marco Hospital and to survey the literature on pediatric CVS treatment, aiming to update the guidance on the most effective treatment strategies for this not-so-uncommon condition. Data from 70 patients with CVS, admitted to our Pediatric Department between September 2011 and December 2021, were aggregated and included in the study. A systematic review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The quality of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool and the A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR-2) method. Treatment responses, as observed both in the literature and in our own experience, are variable. In our cohort, topiramate demonstrated superiority over other pharmacological treatments, exhibiting an efficacy of 85% in the patients treated. A universally accepted treatment protocol for pediatric CVS has yet to be established. The efficacy of first-line treatments is generally suboptimal, suggesting that topiramate might serve as a safe and effective primary therapeutic option for pediatric CVS.


Subject(s)
Vomiting , Humans , Child , Topiramate/therapeutic use , Vomiting/drug therapy , Treatment Outcome
2.
Neuropediatrics ; 54(5): 297-307, 2023 10.
Article in English | MEDLINE | ID: mdl-36948217

ABSTRACT

BACKGROUND: Autosomal dominant mutations of the KCNQ2 gene can cause two epileptic disorders: benign familial neonatal seizures (BFNS) and developmental epileptic encephalopathy (DEE). This systematic review aims to identify the best reported therapy for these patients, relating to phenotype, neurodevelopmental outcome, and an eventual correlation between phenotype and genotype. METHODS: We searched on PubMed using the search terms "KCNQ2" AND "therapy" and "KCNQ2" AND "treatment"; we found 304 articles. Of these, 29 met our criteria. We collected the data from 194 patients. All 29 articles were retrospective studies. RESULTS: In all, 104 patients were classified as DEE and 90 as BFNS. After treatment began, 95% of BFNS patients became seizure free, whereas the seizures stopped only in 73% of those with DEE. Phenobarbital and sodium channel blockers were the most used treatment in BFNS. Most of the DEE patients (95%) needed polytherapy for seizure control and even that did not prevent subsequent developmental impairment (77%).Missense mutations were discovered in 96% of DEE patients; these were less common in BFNS (50%), followed by large deletion (16%), truncation (16%), splice donor site (10%), and frameshift (7%). CONCLUSION: Phenobarbital or carbamazepine appears to be the most effective antiseizure medication for children with a "benign" variant. On the contrary, polytherapy is often needed for DEE patients, even if it does not seem to improve neurological outcomes. In DEE patients, most mutations were located in S4 and S6 helix, which could serve as a potential target for the development of more specific treatment in the future.


Subject(s)
Epilepsy, Benign Neonatal , KCNQ2 Potassium Channel , Child , Infant, Newborn , Humans , Retrospective Studies , KCNQ2 Potassium Channel/genetics , Epilepsy, Benign Neonatal/genetics , Mutation , Seizures , Phenotype , Genotype , Phenobarbital
3.
Ther Hypothermia Temp Manag ; 12(4): 240-244, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36269583

ABSTRACT

Prognostic role of the amplitude-integrated electroencephalography (aEEG) is undeniable, but few works focused on the contribution of medications in misleading its interpretation. We report the case of an asphyxiated newborn enrolled for therapeutic hypothermia (TH) that required the simultaneous use of three anticonvulsants, whose administration resulted in a comatose state and in a switch to a flat trace on the aEEG. The prolonged flat trace on the aEEG, pointing toward a state of irreversible brain damage, led to early stop of TH to prevent therapeutic obstinacy; unexpectedly, once Midazolam was weaned off, the aEEG recovered to a discontinuous pattern. The case emphasizes the aEEG's noninfallibility and advises clinicians to consider the potential misleading effects of depressant medications on its interpretation in asphyxiated newborns undergoing TH.


Subject(s)
Hypothermia, Induced , Hypoxia-Ischemia, Brain , Infant, Newborn, Diseases , Infant, Newborn , Humans , Anticonvulsants/therapeutic use , Hypothermia, Induced/methods , Electroencephalography/methods , Hypoxia-Ischemia, Brain/diagnosis , Hypoxia-Ischemia, Brain/therapy , Infant, Newborn, Diseases/therapy
4.
Sci Rep ; 11(1): 20235, 2021 10 12.
Article in English | MEDLINE | ID: mdl-34642378

ABSTRACT

In these last 25 years, the Neonatal Emergency Transport (NET) service has been widely improved in Italy. To date, all National areas are covered by a NET service; 53 NET centers have been activated in all the Italian territory. Herein, the authors present an observational study to evaluate the rate of infantile mortality after introduction of NET in Sicily, and to study the efficiency of this service in reducing these rates of mortality in vulnerable neonates, transported from primary care birth centers to tertiary facilities to undergo to specialized NICU assistance. All neonates who required an emergency transport by NETS were included. No exclusions criteria were applied. Demographic and regional infantile mortality data, expressed as infant mortality rate, were selected by the official government database (ISTAT- National Statistic Institute- http://www.istat.it ). All data were respectively divided into three groups: data concerning transport, clinical condition, and mortality of the transported patients. We transported by NET 325 neonates. The analysis of the infant mortality rate (per 1.000 live births) in Catania from 2016 to 2018 was reduced compared to the same rate calculated before NETS activation (4.41 index before 2016 vs 4.17 index after 2016). These data showed an increase in other provinces (Enna, Caltanissetta, and Agrigento). 61% of neonates showed a respiratory disease. During the study period the proportion of neonates with a Mortality Index for Neonatal Transportation-MINT < 6 has been reduced, while there was an increase of neonates with higher Transport Risk Index of Physiologic Stability-TRIPS score results. The slight decrease of infantile mortality in Catania during the first three years after introduction of NET follows the same trend of all Italian territories, showing the importance of this service in reducing infantile mortality.


Subject(s)
Infant Mortality/trends , Intensive Care, Neonatal/methods , Respiratory Tract Diseases/epidemiology , Transportation of Patients/methods , Female , Humans , Infant , Infant, Newborn , Male , Respiratory Tract Diseases/mortality , Retrospective Studies , Sicily/epidemiology , Tertiary Care Centers
5.
Early Hum Dev ; 142: 104965, 2020 03.
Article in English | MEDLINE | ID: mdl-32044607

ABSTRACT

BACKGROUND: Non-invasive respiratory ventilation has greatly improved the evolution of respiratory distress in neonates, especially for preterm infants, but few studies have investigated the use of non-invasive ventilation (NIV) in term infants. It is useful for neonatologists and nurses to identify the optimal ventilation strategy in terms of effectiveness for this group of newborns. The aim of our study was to investigate what type of respiratory support between nasal Continuous Positive Airway Pressure (nCPAP) or nasal Biphasic Positive Airway Pressure (nBiPAP) is more effective in term neonates with RDS. METHODS: Our study was a retrospective observational study of 78 full term neonates who were admitted to the NICU at S. Bambino Hospital from December 2015 to December 2016 for respiratory distress at birth. All patients underwent non-invasive ventilation by nCPAP or nBiPAP were included. Oxygen saturations and vital signs were monitored continuously. We evaluated blood gas analysis parameters before treatment and after 1 h of ventilation. RESULTS: During the study period, there were 78 full term newborns admitted in our NICU for neonatal distress who were treated with nCPAP ore nBIPAP ventilation. In nBiPAP patients, we noticed a statistically significant reduction in PaCO2 levels and FiO2 requirement with respect to nCPAP patients, after 1 h of ventilation with a simultaneous significant increase of pH and PaO2 levels. There was no difference in the length of NIV and hospital stay. Among nCPAP patients, two were then intubated and one developed a pneumothorax. CONCLUSION: The results of our study showed that an early BiPAP ventilation on RDS is the more efficient NIV because it improves CO2 removal and reduces FiO2 requirement in comparison to nCPAP. Future studies can clarify if early BiPAP ventilation on RDS is the more efficient of NIV.


Subject(s)
Noninvasive Ventilation/methods , Positive-Pressure Respiration/methods , Respiratory Distress Syndrome, Newborn/therapy , Female , Humans , Infant, Newborn , Male , Noninvasive Ventilation/adverse effects , Positive-Pressure Respiration/adverse effects
6.
Med Hypotheses ; 131: 109296, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31443773

ABSTRACT

BACKGROUND: Among the most common autonomic signs visible in preterm neonates, apnea can represent the first sign of several neurologic and non-neurologic disorders, and seizure is a relatively infrequent cause. Herein authors present a case of neonatal autonomic apnea, discussing the polygraphic video-EEG features of this pathological entity and the differential diagnosis with central apnea and autonomic apnea. CASE REPORT: A female preterm Caucasian infant (29 + 4 weeks' gestational age (GA)), first twin of a twin pregnancy, at birth was intubated and surfactant administration was performed. She was ventilated via invasive ventilation for three days, with subsequent weaning with non-invasive ventilation for other two days, when she stopped requiring any ventilator support. After one week the ventilation weaning, the child presented episodes of cyanosis associated with sudden oxygen desaturation, skin pallor, apnea, and bradycardia. Therefore, the child underwent a continuous video-eeg recording with polygraphic study. The exam showed the presence of apneic episodes with an abrupt and clear start, associated with oxygen desaturation at 70%, with minimal thoracic effort at onset, and then evolving into central apnea. Central apnea lasted about 16 s and presented clear start- and end-points. These episodes were also associated with suppression of the EEG trace in frequency and amplitude, and after about 10 s of central apnea an abrupt decrease of the child's heart rate (more than 50% variation, from 160 bpm to 65 bpm) was recorded. In the suspect of epileptic apneas of autonomic origin, a therapy with oral Levetiracetam, at a starting dose of 10 mg/Kg/day, then increased up to 40 mg/Kg/day, was initiated, and after about 48 h the first administration of the anticonvulsant therapy, no new episodes of cyanosis or electrical apneas were recorded. HYPOTHESIS: Herein the authors suggest to consider the diagnosis of autonomic seizures in those neonates with apneic events associated with EEG suppression. Considering that apnea events are not only present in preterm infants but also in term neonates, it is mandatory to diagnose in this context neonatal seizures for a correct diagnosis and a proper therapeutic choice.


Subject(s)
Apnea/diagnosis , Autonomic Nervous System Diseases/diagnosis , Electroencephalography , Hypoxia/etiology , Infant, Premature, Diseases/diagnosis , Anticonvulsants/therapeutic use , Apnea/classification , Apnea/complications , Apnea/physiopathology , Autonomic Nervous System Diseases/complications , Autonomic Nervous System Diseases/physiopathology , Bradycardia/etiology , Bradycardia/physiopathology , Cyanosis , Diagnosis, Differential , Diseases in Twins , Female , Gestational Age , Humans , Infant, Newborn , Infant, Premature , Levetiracetam/therapeutic use , Seizures/diagnosis , Sleep Apnea, Central/diagnosis , Sleep Apnea, Central/etiology , Sleep Apnea, Central/physiopathology , Video Recording
7.
J Pediatr Hematol Oncol ; 40(4): 269-276, 2018 05.
Article in English | MEDLINE | ID: mdl-29620680

ABSTRACT

BACKGROUND: Triptorelin, a gonadotropin releasing hormone analogue, can be administered to postpubertal female individuals with cancer who receive chemotherapy to obtain menstrual suppression and decrease the risk of hemorrhage caused by thrombocytopenia. Our goal was to assess whether triptorelin also has a protective role against the gonadotoxicity of chemotherapy. PATIENTS AND METHODS: This retrospective observational study includes all postmenarchal female patients who presented to our Unit from 2000 to 2015 and received chemotherapy for cancer. They were administered depot triptorelin. We evaluated long-term ovarian function in order to detect clinical signs of ovarian damage, miscarriages, and pregnancies. Laboratory follow-up consisted in dosing serum follicle stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone. Ultrasound of the ovaries was performed as well. RESULTS: Of 36 evaluable patients, 9 received hematopoietic stem cell transplantation (HSCT). The remaining 27 patients maintained normal ovarian function at clinical, laboratory, and ultrasound assessment. Five of them achieved spontaneous physiological pregnancy. Four of the 9 patients who underwent HSCT developed premature ovarian failure. CONCLUSION: Our study suggests that gonadotropin releasing hormone-a administered during chemotherapy can prevent premature ovarian failure in patients treated without HSCT and that it is not enough to preserve the ovarian function during HSCT. Hence, a prospective randomized trial with a larger population would be recommended.


Subject(s)
Antineoplastic Agents/adverse effects , Fertility Preservation , Neoplasms/drug therapy , Ovary , Primary Ovarian Insufficiency , Triptorelin Pamoate/administration & dosage , Adolescent , Antineoplastic Agents/administration & dosage , Child , Estradiol/blood , Female , Follicle Stimulating Hormone/blood , Follow-Up Studies , Humans , Luteinizing Hormone/blood , Neoplasms/blood , Neoplasms/physiopathology , Ovary/metabolism , Ovary/physiopathology , Primary Ovarian Insufficiency/blood , Primary Ovarian Insufficiency/chemically induced , Primary Ovarian Insufficiency/physiopathology , Primary Ovarian Insufficiency/prevention & control , Progesterone/blood , Prolactin/blood , Retrospective Studies
8.
J Pediatr Hematol Oncol ; 40(3): e191-e194, 2018 04.
Article in English | MEDLINE | ID: mdl-29189509

ABSTRACT

T-lineage ALL is an aggressive disease that needs to be treated with intensive treatment schedules. A late relapse rarely occurs and a clear choice for second-line treatment is on debate. We report on a young adult with a very late isolated extramedullary relapse of PICALM-MLLT10 positive T-ALL, successfully treated with a chemotherapy-based and radiotherapy-based pediatric protocol. We demonstrate that relapse can occur in T-ALL although a SR-MRD behavior treated with a high-risk protocol; specific molecular diagnostic aberrations, as PICALM-MLLT10, are still conserved at very late relapse; a second-line treatment based on pediatric protocol can be effective.


Subject(s)
Chemoradiotherapy/methods , Neoplasm Recurrence, Local/therapy , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Antineoplastic Agents/therapeutic use , Female , Humans , Neoplasm Recurrence, Local/genetics , Neoplasm Recurrence, Local/pathology , Oncogene Proteins, Fusion/genetics , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology , Radiotherapy/methods
9.
World J Gastroenterol ; 19(6): 838-45, 2013 Feb 14.
Article in English | MEDLINE | ID: mdl-23430309

ABSTRACT

Some studies showed that in celiac patients the immunological response to vaccination is similar to that one found in general population except for vaccine against hepatitis B virus (HBV). The non-responsiveness to HBV vaccine has also been described in healthy people, nevertheless the number of non-responders has been demonstrated to be higher in celiac disease (CD) patients than in healthy controls. Several hypothesis explaining this higher rate of unresponsiveness to HBV vaccine in CD patients have been described, such as the genetic hypothesis, according with CD patients carrying the disease-specific haplotype HLA-B8, DR3, and DQ2, show a lower response to HBV vaccine both in clinical expressed CD patients and in healthy people carrying the same haplotype. On the other hand, it has been demonstrated that the gluten intake during the vaccination seems to influence the response to the same vaccine. Moreover, it has been demonstrated a possible genetic predisposition to hepatitis B vaccine non-responsiveness likely due to the presence of specific human leukocyte antigen haplotypes and specific single nucleotide polymorphism in genes of cytokine/cytokine receptors and toll like receptors, but the pathogenic mechanism responsible for this low responsiveness still remains unclear. The aim of this review is to focus on the possible pathogenic causes of unresponsiveness to HBV vaccine in CD patients and to propose an alternative vaccination schedule in order to improve the responsiveness to HBV vaccine in this at-risk patients.


Subject(s)
Celiac Disease/immunology , Hepatitis B Vaccines/administration & dosage , Hepatitis B/prevention & control , Vaccination , Celiac Disease/epidemiology , Celiac Disease/history , Hepatitis B/epidemiology , Hepatitis B/history , Hepatitis B/immunology , Hepatitis B Vaccines/history , Hepatitis B Vaccines/immunology , History, 20th Century , History, 21st Century , Humans , Immunization Schedule , Risk Factors , Treatment Failure , Vaccination/history , Vaccination/trends
10.
Ital J Pediatr ; 38: 35, 2012 Jul 23.
Article in English | MEDLINE | ID: mdl-22824011

ABSTRACT

The most frequent symptoms among the manifestations of cow milk protein allergy (CMPA) are gastrointestinal. CMPA pathogenesis involves immunological mechanisms with participation of immunocompetent cells and production of immunoglobulin E (IgE). Nevertheless, recent studies have been focused on the description of other forms of CMPA, not-mediated by IgE reactions, mostly involving the T lymphocite immune system. Thus, in this field it is important to note how different kind of cells are involved in the immunopathogenesis of CMPA, such as antigen-specific T cells, T regulatory cells, cytokines secreted by the different T lymphocite subsets, B lymphocytes, antingen-presenting cells, mast cells, that together orchestrate the complex mechanism leading to the phenotipic expression of CMPA.The progress in the diagnosis of immunologic disorders allowed the recent literature to develop new models for immuno-mediate disorders, involving new cells (such as Treg cells) and thus allowing the acquisition of a new vision of the pathogenesis of atopic diseases.The aim of this review is to describe the immunopathogenetic aspects of CMPA in view of these new discoveries in the immunologic field, considering the immunologic pathway at the basis of both IgE- and not-IgE mediated CMPA.


Subject(s)
Milk Hypersensitivity/immunology , Milk Proteins/immunology , Animals , Cattle , Child , Female , Humans , Immunoglobulin E/immunology , Probiotics/pharmacology , T-Lymphocytes, Regulatory/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...